- Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drugJupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.Fierce Biotech · 3d ago↗ source
- Agios says adios to sickle cell program over lackluster phase 2 dataA phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for t…Fierce Biotech · 3d ago↗ source
- Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.